Novel BRAF gene fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers
P. Jain, L. F. Surrey, J. Straka, P. Russo, R. Womer, M. Li, P. B. Storm, A. J. Waanders, M. D. Hogarty, A. C. Resnick, J. Picarsic
The paper identifies two novel BRAF gene fusions in pediatric histiocytic neoplasms and shows they respond differently to RAF inhibitor therapies due to distinct dimerization mechanisms.
bioRxiv · Apr 13, 2020Cancer Biology